Aclaris Therapeutics Prices $50 Million Stock and Pre-Funded Warrant Offering
Aclaris Therapeutics announced pricing of a $50.0 million offering of common stock and pre-funded warrants.
Related stories
Restaurant Brands International Reports Third-Quarter Profit
M impact | EQUITY | Oct 29, 2026, 03:57 PM UTC
WPP Reports 2% Third-Quarter Net Revenue Decline
M impact | EQUITY | Oct 29, 2026, 03:43 PM UTC
Petrobras Reports Record Third-Quarter Production; Ambev Profit Falls 10%
The headline reports record production at Petrobras in the third quarter and a 10% decline in Ambev's profit.
M impact | EQUITY | Oct 29, 2026, 03:43 PM UTC
Renault Reports Higher Third-Quarter Revenue
M impact | EQUITY | Oct 29, 2026, 03:42 PM UTC
Keytruda Maker Reports Third-Quarter Profit Above Expectations
The pharmaceutical company reported third-quarter profit above expectations.
M impact | EQUITY | Oct 29, 2026, 03:42 PM UTC
Volkswagen Workers Accept 8.24% Pay Increase, Averting Strike
Volkswagen workers accepted a 8.24% wage increase after a vote, according to the headline.
M impact | EQUITY | Oct 29, 2026, 03:42 PM UTC